SXTP (60 Degrees Pharmaceuticals) Institutional Ownership: 7.31% (As of Jul. 11, 2026)


SXTP 60 Degrees Pharmaceuticals Inc SXTP
44 GF Score
Price $1.55
GF Value $2.03
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 60 Degrees Pharmaceuticals Institutional Ownership?

60 Degrees Pharmaceuticals SXTP 44 Institutional Ownership is 7.31% as of Jul. 11, 2026. GuruFocus rates SXTP with a GF Score™ of 44/100 and a GF Value™ of $2.03 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 60 Degrees Pharmaceuticals's institutional ownership is 7.31%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 60 Degrees Pharmaceuticals's Insider Ownership is 4.28%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 60 Degrees Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.09%.

60 Degrees Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for 60 Degrees Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

60 Degrees Pharmaceuticals Institutional Ownership Chart

60 Degrees Pharmaceuticals Historical Data

The historical data trend for 60 Degrees Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 2.20 2.20 2.20 0.27 0.27 0.77 0.64 0.62 0.61 0.45
SXTP
44GF Score
60 Degrees Pharmaceuticals Inc SXTP
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

60 Degrees Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 7.31% mean?
60 Degrees Pharmaceuticals (SXTP) has a Institutional Ownership of 7.31% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on 60 Degrees Pharmaceuticals and its competitors.
Is 60 Degrees Pharmaceuticals' Institutional Ownership too high?
60 Degrees Pharmaceuticals' current Institutional Ownership is 7.31%. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Institutional Ownership compare to GLMD and FBLG?
60 Degrees Pharmaceuticals' Institutional Ownership of 7.31% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on 60 Degrees Pharmaceuticals and its competitors. 60 Degrees Pharmaceuticals's current Institutional Ownership is 7.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.03, compared to a current price of $1.55 — trading 23.6% below its estimated fair value. The current Institutional Ownership is 7.31%. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Institutional Ownership is 7.31% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?

Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued. The current stock price of $1.55 is trading 23.6% below its estimated GF Value™ of $2.03. GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for SXTP:

  • Institutional Ownership: 7.31%
  • GF Value™: $2.03 vs. price of $1.55 (23.6% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

60 Degrees Pharmaceuticals Business Description

Address 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score

Get the complete analysis for SXTP

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$2.03
GF Value